76 related articles for article (PubMed ID: 17882279)
1. Acute-myeloid-leukemia-targeted toxins kill tumor cells by cell-type-specific mechanisms and synergize with TRAIL to allow manipulation of the extent and mechanism of tumor cell death.
Horita H; Frankel AE; Thorburn A
Leukemia; 2008 Mar; 22(3):652-5. PubMed ID: 17882279
[No Abstract] [Full Text] [Related]
2. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
[TBL] [Abstract][Full Text] [Related]
3. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity.
Liu TF; Urieto JO; Moore JE; Miller MS; Lowe AC; Thorburn A; Frankel AE
Exp Hematol; 2004 Mar; 32(3):277-81. PubMed ID: 15003313
[TBL] [Abstract][Full Text] [Related]
4. A recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor receptor.
Bendel AE; Shao Y; Davies SM; Warman B; Yang CH; Waddick KG; Uckun FM; Perentesis JP
Leuk Lymphoma; 1997 Apr; 25(3-4):257-70. PubMed ID: 9168436
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis by leukemia cell-targeted diphtheria toxin occurs via receptor-independent activation of Fas-associated death domain protein.
Thorburn J; Frankel AE; Thorburn A
Clin Cancer Res; 2003 Feb; 9(2):861-5. PubMed ID: 12576460
[TBL] [Abstract][Full Text] [Related]
6. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias.
Frankel AE; McCubrey JA; Miller MS; Delatte S; Ramage J; Kiser M; Kucera GL; Alexander RL; Beran M; Tagge EP; Kreitman RJ; Hogge DE
Leukemia; 2000 Apr; 14(4):576-85. PubMed ID: 10764142
[TBL] [Abstract][Full Text] [Related]
7. Effects of mast cell growth factor on acute myeloid leukemia cells in vitro: effects of combinations with other cytokines.
Budel LM; Delwel R; van Buitenen C; Hoogerbrugge H; Löwenberg B
Leukemia; 1993 Mar; 7(3):426-34. PubMed ID: 7680401
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte-macrophage colony-stimulating factor receptor-targeted therapy of chemotherapy- and radiation-resistant human myeloid leukemias.
Perentesis JP; Bendel AE; Shao Y; Warman B; Davies SM; Yang CH; Chandan-Langlie M; Waddick KG; Uckun FM
Leuk Lymphoma; 1997 Apr; 25(3-4):247-56. PubMed ID: 9168435
[TBL] [Abstract][Full Text] [Related]
9. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials.
Urieto JO; Liu T; Black JH; Cohen KA; Hall PD; Willingham MC; Pennell LK; Hogge DE; Kreitman RJ; Frankel AE
Protein Expr Purif; 2004 Jan; 33(1):123-33. PubMed ID: 14680969
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
Perentesis JP; Waddick KG; Bendel AE; Shao Y; Warman BE; Chandan-Langlie M; Uckun FM
Clin Cancer Res; 1997 Mar; 3(3):347-55. PubMed ID: 9815691
[TBL] [Abstract][Full Text] [Related]
11. Recombinant fusion toxins directed against the human granulocyte-macrophage colony stimulating factor (GM-CSF) receptor.
Shao Y; Warman BE; Perentesis JP
Methods Mol Biol; 2001; 166():31-53. PubMed ID: 11217375
[No Abstract] [Full Text] [Related]
12. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF.
Frankel AE; Hall PD; McLain C; Safa AR; Tagge EP; Kreitman RJ
Bioconjug Chem; 1998; 9(4):490-6. PubMed ID: 9667951
[TBL] [Abstract][Full Text] [Related]
13. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors.
Plasilova M; Zivny J; Jelinek J; Neuwirtova R; Cermak J; Necas E; Andera L; Stopka T
Leukemia; 2002 Jan; 16(1):67-73. PubMed ID: 11840265
[TBL] [Abstract][Full Text] [Related]
14. Over-expressing CYLD augments antitumor activity of TRAIL by inhibiting the NF-κB survival signaling in lung cancer cells.
Deng LL; Shao YX; Lv HF; Deng HB; Lv FZ
Neoplasma; 2012; 59(1):18-29. PubMed ID: 22017589
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
[TBL] [Abstract][Full Text] [Related]
16. Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein.
Frankel AE; Beran M; Hogge DE; Powell BL; Thorburn A; Chen YQ; Vallera DA
Exp Hematol; 2002 Nov; 30(11):1316-23. PubMed ID: 12423685
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
18. The flavonolignan silibinin potentiates TRAIL-induced apoptosis in human colon adenocarcinoma and in derived TRAIL-resistant metastatic cells.
Kauntz H; Bousserouel S; Gossé F; Raul F
Apoptosis; 2012 Aug; 17(8):797-809. PubMed ID: 22555452
[TBL] [Abstract][Full Text] [Related]
19. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
20. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice.
Black JH; McCubrey JA; Willingham MC; Ramage J; Hogge DE; Frankel AE
Leukemia; 2003 Jan; 17(1):155-9. PubMed ID: 12529673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
